Donald Lannin, MD
Professor Emeritus of Surgery (Oncology)Cards
About
Titles
Professor Emeritus of Surgery (Oncology)
Biography
Dr. Lannin graduated from the University of Minnesota where he also completed his General Surgery residency and went on to do a fellowship in oncology funded by the National Institutes of Health. He rose through the ranks to Professor of Surgery at East Carolina University and joined the faculty at Yale in 2002. With nearly 30 years of experience in surgery, he has been instrumental in building The Breast Center -- Smilow Cancer Hospital at Yale-New Haven, serving as its Executive Director from 2002 to 2010.
Departments & Organizations
Education & Training
- Resident
- University of Minnesota Minneapolis, MN (1982)
- Fellow
- National Institutes of Health (1980)
- Intern
- University of Minnesota Minneapolis, MN (1975)
- MD
- University of Minnesota (1974)
- BA
- Stanford University (1970)
Research
Overview
Medical Research Interests
Breast Diseases; Breast Neoplasms; Surgical Oncology
Publications
2022
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers. Clinical Breast Cancer 2022, 23: 199-210. PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaTriple-negative breast cancerHigh histologic gradeApocrine differentiationAMACR expressionEstrogen receptorApocrine DCISER-/PRHistologic gradeProgesterone receptorApocrine featuresBreast cancerHuman epidermal growth factor 2 (HER2) statusLack of ERDistant metastasis-free survivalDiagnostic markerInitial N stageLack estrogen receptorApocrine breast cancerLymph node metastasisNegative breast cancerAndrogen receptor mRNACoA racemase expressionBenign breast tissueBreast cancer cohortBreast Cancer Screening: Is There Room for De-escalation?
Kim L, Lannin D. Breast Cancer Screening: Is There Room for De-escalation? Current Breast Cancer Reports 2022, 14: 153-161. PMID: 36404936, PMCID: PMC9640864, DOI: 10.1007/s12609-022-00465-z.Peer-Reviewed Original ResearchASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates
Le Blanc J, Golshan M, Lannin D, Greenup R, Berger E, Saridakis A, Horowitz N, Zanieski G, Avraham T, Mastrioanni M, Park T. ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates. Annals Of Surgical Oncology 2022, 29: 2191-2192. DOI: 10.1245/s10434-021-10944-9.Peer-Reviewed Original ResearchThe Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients
Trant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients. Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.Peer-Reviewed Original ResearchConceptsTumor volumeBlack cohoshSitu patientsDuctal carcinomaAnti-inflammatory effectsTumor cellular proliferationBreast cancer treatmentCellular proliferationWilcoxon signed-rank testDCIS patientsAdverse eventsEligible subjectsWindow trialsCore biopsyInvasive diseaseKi67 expressionSigned-rank testBreast cancerGrade 3Hormone changesPatientsQuantitative immunofluorescenceBC extractSignificant toxicityCancer treatment
2021
ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation Surgery
Chagpar A, Berger E, Alperovich M, Zanieski G, Avraham T, Lannin D. ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation Surgery. Annals Of Surgical Oncology 2021, 28: 632-632. DOI: 10.1245/s10434-021-10584-z.Peer-Reviewed Original ResearchHow did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original ResearchThe effect of black cohosh on Ki67 levels in DCIS patients.
Hofstatter E, Trant A, Stavris K, Horowitz N, Killelea B, Lannin D, Neumeister V, Rimm D, Chagpar A. The effect of black cohosh on Ki67 levels in DCIS patients. Journal Of Clinical Oncology 2018, 36: e13541-e13541. DOI: 10.1200/jco.2018.36.15_suppl.e13541.Peer-Reviewed Original Research
2017
Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer
Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalLN evaluationPositive breast cancerOverall survivalBreast cancerHormone receptor-positive breast cancerWomen Aged 70 YearsReceptor-positive breast cancerLymph node evaluationCancer-specific survivalLower hazard rateLN surgeryBetter OSPatient ageSEER databasePatient selectionTumor characteristicsSEER dataPatientsNode evaluationHormone receptorsCancerSurvivalTreatment variablesNCDBRegional variation in breast cancer surgery: Results from the National Cancer Database (NCDB)
Chiu AS, Thomas P, Killelea BK, Horowitz N, Chagpar AB, Lannin DR. Regional variation in breast cancer surgery: Results from the National Cancer Database (NCDB). The American Journal Of Surgery 2017, 214: 907-913. PMID: 28736057, DOI: 10.1016/j.amjsurg.2017.07.008.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- December 08, 2023
Disparities in Breast Reconstruction Rates After Mastectomies for Older Asian American and South Korean Women
- June 02, 2021
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as Connecticut Magazine 'Best Doctors'
- July 03, 2020Source: Vogue
This New Study Finds That Breast Cancer Is Detected Earlier in States With Expanded Medicaid
- July 01, 2020
Yale Cancer Center Study Shows Breast Cancer Detected Earlier in States with Expanded Medicaid Coverage
Get In Touch
Contacts
Academic Office Number
Appointment Number
Clinic Fax Number